Ting Jiang1, Yiyang Luo1, Binbin Wang2. 1. First Clinical Medical College, Zhejiang Chinese Medical University. 2. Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Abstract
RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side effect has not been observed in the follow-up during the treatment of the third-generation EGFR-TKI Almonertinib (also called HS-10296). Here, we first report an Almonertinib-induced ILD in an elderly female patient. PATIENT CONCERNS: A 70-year-old female diagnosed with " lung adenocarcinoma with intracranial metastasis" harboring a mutation of EGFR 19DEL was administrated with Almonertinib 110 mg orally as the first-line treatment. However, she presented with chest tightness, and shortness of breath, accompanying with paroxysmal dry cough 3 months after the initiation of Almonertinib. DIAGNOSES: Extensive relevant examinations did not provide conclusive results and the chest computed tomography showed a diffuse ILD in bilateral pulmonary. INTERVENTIONS: The patient was diagnosed with Almonertinib-induced ILD in the absence of no other potential causes. She discontinued Almonertinib and was treated with oxygen uptaken and methylprednisolone. OUTCOMES: The whole symptoms were eliminated and the chest computed tomography showed ILD got remission after the prescription of methylprednisolone. LESSONS: Almonertinib has potential to cause the rare but severe interstitial lung disease. Clinicians should keep cautious of this when prescribing Almonertinib.
RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side effect has not been observed in the follow-up during the treatment of the third-generation EGFR-TKI Almonertinib (also called HS-10296). Here, we first report an Almonertinib-induced ILD in an elderly female patient. PATIENT CONCERNS: A 70-year-old female diagnosed with " lung adenocarcinoma with intracranial metastasis" harboring a mutation of EGFR 19DEL was administrated with Almonertinib 110 mg orally as the first-line treatment. However, she presented with chest tightness, and shortness of breath, accompanying with paroxysmal dry cough 3 months after the initiation of Almonertinib. DIAGNOSES: Extensive relevant examinations did not provide conclusive results and the chest computed tomography showed a diffuse ILD in bilateral pulmonary. INTERVENTIONS: The patient was diagnosed with Almonertinib-induced ILD in the absence of no other potential causes. She discontinued Almonertinib and was treated with oxygen uptaken and methylprednisolone. OUTCOMES: The whole symptoms were eliminated and the chest computed tomography showed ILD got remission after the prescription of methylprednisolone. LESSONS: Almonertinib has potential to cause the rare but severe interstitial lung disease. Clinicians should keep cautious of this when prescribing Almonertinib.
Authors: Y-L Wu; D Planchard; S Lu; H Sun; N Yamamoto; D-W Kim; D S W Tan; J C-H Yang; M Azrif; T Mitsudomi; K Park; R A Soo; J W C Chang; A Alip; S Peters; J-Y Douillard Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt Journal: J Clin Oncol Date: 2017-10-12 Impact factor: 44.544
Authors: C Leduc; J P Merlio; B Besse; H Blons; D Debieuvre; P P Bringuier; I Monnet; I Rouquette; S Fraboulet-Moreau; A Lemoine; D Pouessel; J Mosser; F Vaylet; A Langlais; P Missy; F Morin; D Moro-Sibilot; J Cadranel; F Barlesi; M Beau-Faller Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976